4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 99 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q4 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,361 | -29.5% | 264 | 0.0% | 0.00% | – |
| Q2 2023 | $4,770 | +90.0% | 264 | +133.6% | 0.00% | – |
| Q4 2022 | $2,510 | -16.3% | 113 | -69.6% | 0.00% | – |
| Q3 2022 | $3,000 | -40.0% | 372 | -48.6% | 0.00% | – |
| Q2 2022 | $5,000 | -76.2% | 724 | -48.4% | 0.00% | – |
| Q1 2022 | $21,000 | +31.2% | 1,404 | +98.0% | 0.00% | – |
| Q4 2021 | $16,000 | +77.8% | 709 | +123.0% | 0.00% | – |
| Q3 2021 | $9,000 | – | 318 | +1490.0% | 0.00% | – |
| Q2 2021 | $0 | – | 20 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 377,777 | $15,659,000 | 5.43% |
| BVF INC/IL | 1,106,070 | $45,847,000 | 1.80% |
| Eagle Health Investments LP | 50,000 | $2,073,000 | 1.33% |
| Ally Bridge Group (NY) LLC | 150,000 | $6,218,000 | 1.07% |
| Casdin Capital, LLC | 780,555 | $32,354,000 | 0.96% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $163,227,000 | 0.45% |
| Pinz Capital Management, LP | 19,900 | $825,000 | 0.38% |
| ArrowMark Colorado Holdings LLC | 1,063,744 | $44,092,000 | 0.34% |
| Perceptive Advisors | 600,256 | $24,881,000 | 0.27% |
| ACUTA CAPITAL PARTNERS, LLC | 20,000 | $829,000 | 0.23% |